Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5N1 pandemic influenza virus-like particle vaccine
- Development stage
- Phase 1
- Lead developer
- Novavax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **H5N1 pandemic influenza virus-like particle vaccine** is an investigational vaccine comprised of virus-like particles (VLPs) containing hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins from the influenza A/Indonesia/05/2005 (H5N1) strain (clade 2.1), produced in Sf9 insect cells. It elicits humoral immune responses, including hemagglutination inhibition (HAI) and microneutralization (MN) antibodies, with cross-reactivity against other clade 2 subtypes, as demonstrated in dose-ranging studies using 15, 45, or 90 μg HA/dose. Developed under a BARDA contract, it advanced to an FDA-approved phase I/II clinical trial involving 230 healthy adults, showing seroconversion rates up to 100% with adjuvants and good tolerability, positioning it as a promising platform for pandemic preparedness due to its economical production and potent immunogenicity.[7]
- Other names
- A/Indonesia/05/2005 (H5N1) VLP vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)HA (Hemagglutinin)
Beyond the preview
Go deeper on H5N1 pandemic influenza virus-like particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5N1 pandemic influenza virus-like particle vaccine.